Stay updated on Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Sign up to get notified when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.

Latest updates to the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded mentions of Multiple Myeloma and related topics (MedlinePlus Genetics) and the revision note 'Revision: v3.3.2'. The PubMed publications boilerplate was revised with a note 'Revision: v3.2.0'.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page no longer displays the government funding/status notice banner at the top.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page no longer shows the topic 'Multiple Myeloma' and omits the related topic 'MedlinePlus Genetics'. This reduces the disease-focused context and keyword associations used for discovery.SummaryDifference0.3%

- Check56 days agoChange DetectedRemoved MedlinePlus Genetics topic on multiple myeloma (a core medical topic).SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a MedlinePlus Genetics topic for multiple myeloma, expanding core content with genetics information about this disease.SummaryDifference0.1%

- Check70 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

Stay in the know with updates to Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Belantamab Mafodotin vs Pom/Dex in RRMM Clinical Trial page.